Cytokinetics News and Activities
Presence
Cytokinetics develops muscle-focused medicines for heart and muscle diseases. It provides drug research and clinical development services and serves patients, hospitals, and healthcare providers.
Cytokinetics products and services overview:
- Heart disease drugs
- Muscle disease drugs
- Clinical development
- Drug discovery
- Research partnerships
Revenue: ~$330 million
Employees: 550
Headquarters: South San Francisco, United States (USA)
Cytokinetics is one of the...
Cytokinetics is a company listed under the stock ticker CYTK (US).
Acquisition, funding and merger involving Cytokinetics.
- Cytokinetics has just announced a $805 Million fundraising (posted on May 12 2026).
Executives
View the org chart displaying its 50 main executives
Most searched biographies at Cytokinetics
- Robert Blum, President, Chief Executive Officer, Director
- Lynne Parshall, Director
- Muna Bhanji, Director
Popular executive movements at Cytokinetics
- Jeffrey Hessekiel has joined the company as Executive Vice President, Chief Legal Officer (posted on November 17 2025).
Create your alert
to follow the executive moves at Cytokinetics.
Biotechnology
Cytokinetics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
- NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (posted on June 1 2026)..
Popular contacts in Biotechnology
News
Press releases by Cytokinetics
- Cytokinetics Announces Fourth Annual Communications Fellowship Grant Program Call for Proposals | Cytokinetics, Inc.
- Cytokinetics to Host Analyst & Investor Day on October 7, 2021 | Cytokinetics, Inc.
- Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting | Cytokinetics, Inc.
- Cytokinetics to Participate in September Investor Conferences | Cytokinetics, Inc.
- Cytokinetics to Host Investor Call and Webcast to Discuss the Full Results From Redwood-HCM at the HFSA Annual Scientific Meeting | Cytokinetics, Inc.
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Cytokinetics, Inc.
- Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF to Be Presented in Late Breaking Clinical Trials Session at the HFSA Annual Scientific Meeting | Cytokinetics, Inc.
- Reldesemtiv Effects Maintained in ALS When Used With Rilutek, Radicava, New Trial Analysis Shows
- Reldesemtiv Earns FDA’s Orphan Drug Designation for ALS Treatment
- Reldesemtiv Wins ALS Treatment Orphan Drug Designation From EMA
- View more press releases Close
Social media about Cytokinetics
- Cytokinetics on Wikipedia, Google News & Yahoo Finance
- Cytokinetics on LinkedIn, X (Twitter) & YouTube
